PE20220937A1 - Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos - Google Patents
Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismosInfo
- Publication number
- PE20220937A1 PE20220937A1 PE2022000120A PE2022000120A PE20220937A1 PE 20220937 A1 PE20220937 A1 PE 20220937A1 PE 2022000120 A PE2022000120 A PE 2022000120A PE 2022000120 A PE2022000120 A PE 2022000120A PE 20220937 A1 PE20220937 A1 PE 20220937A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- ring
- carboxamido
- compound
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula general (I), su forma tautomerica, su estereoisomero, su sal farmaceuticamente aceptable, donde: G1 es -CH2- o -CH(CH2)n-anillo A-; G2 es -CH=CH-; el anillo A es heterociclilo o heteroarilo opcionalmente sustituido; el anillo B es un anillo aromatico; el anillo C es heteroarilo de cinco miembros opcionalmente sustituido; R1 es heteroarilo opcionalmente sustituido, entre otros; R2 es hidrogeno, alquilo C1-C6 opcionalmente sustituido y cicloalquilo C3-C5 monociclico opcionalmente sustituido; o y m son 1; p es 0 a 2. Son compuestos especificos: acido (1S,4S)-4-((E)-12-carbamoil-1,15-bis(1-etil-3-metil-1H-pirazol-5-carboxamido)-8,9,16,19-tetrahidro-7H-6,10-dioxa-2,14,15a,19a-tetraazaciclopentadeca[3,2,1-cd:8,9,10-c'd']diinden-4-carboxamido)ciclohexano-1-carboxilico (Compuesto 1); acido (1R,4R)-4-((E)-12-carbamoil-1,15-bis(1-etil-3-metil-1H-pirazol-5-carboxamido)-8,9,16,19-tetrahidro-7H-6,10-dioxa-2,14,15a,19a-tetraazaciclopentadeca[3,2,1-cd:8,9,10-c'd']diinden-4-carboxamido)ciclohexano-1-carboxilico (Compuesto 2); entre otros. Tambien se refiere a una composicion farmaceutica. Dicho compuesto es un modulador de una proteina estimulador de genes de interferon (STING) y/o un complejo proteico STING, siendo util en el tratamiento del cancer y enfermedades infecciosas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029556 | 2019-07-22 | ||
| IN201921051086 | 2019-12-10 | ||
| IN202021003961 | 2020-01-29 | ||
| PCT/IB2020/056875 WO2021014365A1 (en) | 2019-07-22 | 2020-07-22 | Macrocyclic compounds as sting agonists and methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220937A1 true PE20220937A1 (es) | 2022-05-31 |
Family
ID=72422197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000120A PE20220937A1 (es) | 2019-07-22 | 2020-07-22 | Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US12479858B2 (es) |
| EP (1) | EP4004002B1 (es) |
| JP (1) | JP7592689B2 (es) |
| KR (1) | KR20220035955A (es) |
| CN (1) | CN114174303B (es) |
| AU (1) | AU2020319058B2 (es) |
| BR (1) | BR112022001125A2 (es) |
| CA (1) | CA3147397A1 (es) |
| CL (1) | CL2022000145A1 (es) |
| CO (1) | CO2022001814A2 (es) |
| CR (1) | CR20220029A (es) |
| DK (1) | DK4004002T3 (es) |
| EC (1) | ECSP22005485A (es) |
| ES (1) | ES2989915T3 (es) |
| FI (1) | FI4004002T3 (es) |
| GE (2) | GEAP202415883A (es) |
| HR (1) | HRP20241222T1 (es) |
| HU (1) | HUE068456T2 (es) |
| IL (1) | IL289740B2 (es) |
| LT (1) | LT4004002T (es) |
| MA (1) | MA56674B1 (es) |
| MX (1) | MX420195B (es) |
| PE (1) | PE20220937A1 (es) |
| PH (1) | PH12022550175A1 (es) |
| PL (1) | PL4004002T3 (es) |
| PT (1) | PT4004002T (es) |
| RS (1) | RS66126B1 (es) |
| SA (1) | SA522431429B1 (es) |
| SI (1) | SI4004002T1 (es) |
| SM (1) | SMT202400399T1 (es) |
| UA (1) | UA129653C2 (es) |
| WO (1) | WO2021014365A1 (es) |
| ZA (1) | ZA202201375B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019011655A (es) | 2017-03-29 | 2019-12-19 | Legochem Biosciences Inc | Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este. |
| EP4003978B1 (en) | 2019-07-22 | 2024-05-01 | Boehringer Ingelheim International GmbH | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway or fibrotic diseases |
| US11155567B2 (en) | 2019-08-02 | 2021-10-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
| BR112022019919A2 (pt) | 2020-04-02 | 2023-02-14 | Mersana Therapeutics Inc | Conjugado de anticorpo-fármaco compreendendo agonistas de sting |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| JP2024503508A (ja) * | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | 免疫調節性抗体－薬物コンジュゲート |
| UY39705A (es) * | 2021-03-30 | 2022-10-31 | Jacobio Pharmaceuticals Co Ltd | Novedosos compuestos útiles como agonistas de sting y sus usos |
| CN120513246A (zh) * | 2022-12-22 | 2025-08-19 | 阿库勒斯治疗私人有限公司 | 用于调节sting的苯并咪唑衍生物 |
| AR133167A1 (es) * | 2023-07-07 | 2025-09-03 | Hoffmann La Roche | Macrociclos para el tratamiento de enfermedad autoinmunitaria |
| AR133266A1 (es) * | 2023-07-19 | 2025-09-10 | Hoffmann La Roche | Macrociclos para el tratamiento de enfermedades autoinmunitarias |
| CN119490423A (zh) * | 2023-08-15 | 2025-02-21 | 沈阳中化农药化工研发有限公司 | 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
| AR046959A1 (es) | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| CA3052368A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors |
| JP2009540013A (ja) | 2006-06-15 | 2009-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アニリノ−４−（複素環）アミノ−ピリミジン |
| WO2008090570A1 (en) | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Novel antimicrobials |
| TW201000447A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| EP2651926A4 (en) * | 2010-12-15 | 2014-07-09 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| MX2015007862A (es) | 2012-12-28 | 2016-02-05 | Nippon Zoki Pharmaceutical Co | Derivado de amida del acido cinamico. |
| ES2692226T3 (es) * | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| JOP20170083B1 (ar) * | 2016-04-07 | 2022-03-14 | Glaxosmithkline Ip Dev Ltd | أميدات هتيروسيكلية مفيدة كمعدلات بروتين |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| KR102499780B1 (ko) | 2016-05-27 | 2023-02-16 | 항저우 인노게이트 파마 컴퍼니 리미티드 | Fgfr4 저해제인 헤테로 고리 화합물 |
| EA036338B1 (ru) * | 2017-02-22 | 2020-10-28 | Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед | Гетероциклические амиды, пригодные в качестве модуляторов белков |
| US20200172483A1 (en) | 2017-06-22 | 2020-06-04 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
| KR102628892B1 (ko) | 2017-06-22 | 2024-01-24 | 큐라데브 파마 리미티드 | 인간 sting의 소분자 조절제 |
| WO2018234805A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Small molecule modulators of human sting |
| WO2019023635A1 (en) | 2017-07-27 | 2019-01-31 | Stingray Therapeutics, Inc. | SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER |
| CA3071538A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene sting agonists for cancer treatment |
| JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ |
| BR112020006780A2 (pt) * | 2017-10-05 | 2020-10-06 | Glaxosmithkline Intellectual Property Development Limited | moduladores do estimulador de genes do interferon (sting) |
| TW201927771A (zh) * | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| WO2020194160A1 (en) | 2019-03-28 | 2020-10-01 | Lupin Limited | Macrocyclic compounds as sting agonists |
-
2020
- 2020-07-22 MX MX2022000939A patent/MX420195B/es unknown
- 2020-07-22 PH PH1/2022/550175A patent/PH12022550175A1/en unknown
- 2020-07-22 SM SM20240399T patent/SMT202400399T1/it unknown
- 2020-07-22 FI FIEP20768090.1T patent/FI4004002T3/fi active
- 2020-07-22 JP JP2022504707A patent/JP7592689B2/ja active Active
- 2020-07-22 UA UAA202200745A patent/UA129653C2/uk unknown
- 2020-07-22 CN CN202080053237.XA patent/CN114174303B/zh active Active
- 2020-07-22 CR CR20220029A patent/CR20220029A/es unknown
- 2020-07-22 US US17/628,619 patent/US12479858B2/en active Active
- 2020-07-22 PE PE2022000120A patent/PE20220937A1/es unknown
- 2020-07-22 LT LTEPPCT/IB2020/056875T patent/LT4004002T/lt unknown
- 2020-07-22 WO PCT/IB2020/056875 patent/WO2021014365A1/en not_active Ceased
- 2020-07-22 DK DK20768090.1T patent/DK4004002T3/da active
- 2020-07-22 GE GEAP202415883A patent/GEAP202415883A/en unknown
- 2020-07-22 PL PL20768090.1T patent/PL4004002T3/pl unknown
- 2020-07-22 ES ES20768090T patent/ES2989915T3/es active Active
- 2020-07-22 PT PT207680901T patent/PT4004002T/pt unknown
- 2020-07-22 KR KR1020227005943A patent/KR20220035955A/ko active Pending
- 2020-07-22 HU HUE20768090A patent/HUE068456T2/hu unknown
- 2020-07-22 RS RS20241052A patent/RS66126B1/sr unknown
- 2020-07-22 EP EP20768090.1A patent/EP4004002B1/en active Active
- 2020-07-22 HR HRP20241222TT patent/HRP20241222T1/hr unknown
- 2020-07-22 GE GEAP202015883A patent/GEP20247627B/en unknown
- 2020-07-22 BR BR112022001125A patent/BR112022001125A2/pt unknown
- 2020-07-22 MA MA56674A patent/MA56674B1/fr unknown
- 2020-07-22 AU AU2020319058A patent/AU2020319058B2/en active Active
- 2020-07-22 CA CA3147397A patent/CA3147397A1/en active Pending
- 2020-07-22 IL IL289740A patent/IL289740B2/en unknown
- 2020-07-22 SI SI202030501T patent/SI4004002T1/sl unknown
-
2022
- 2022-01-19 SA SA522431429A patent/SA522431429B1/ar unknown
- 2022-01-21 CL CL2022000145A patent/CL2022000145A1/es unknown
- 2022-01-21 EC ECSENADI20225485A patent/ECSP22005485A/es unknown
- 2022-01-28 ZA ZA2022/01375A patent/ZA202201375B/en unknown
- 2022-02-21 CO CONC2022/0001814A patent/CO2022001814A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220937A1 (es) | Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| JP2025114536A (ja) | 免疫調節剤としての１，２，４－オキサジアゾールおよびチアジアゾール化合物 | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| ECSP19076732A (es) | Compuestos de heteroarilo bicíclicos 66 fusionados y su uso como inhibidores de lats | |
| EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
| EA201991316A1 (ru) | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту | |
| PE20190705A1 (es) | COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING | |
| BR112014009306B1 (pt) | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| EA200500286A1 (ru) | Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) | |
| CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
| UY33473A (es) | Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus | |
| PE20220169A1 (es) | Compuestos macrociclicos como agonistas de sting | |
| PH12016502251A1 (en) | Peptides as oxytocin agonists | |
| PE20211447A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas | |
| MX2024010104A (es) | Compuesto bicíclico condensado que contiene pirrolinona. | |
| AR050914A1 (es) | Agonista receptor de vasopresina peptidico | |
| CL2025001273A1 (es) | Compuesto bicíclico fusionado | |
| MX2025006990A (es) | Compuesto quimerico protac, metodo de preparacion del mismo y uso del mismo | |
| AR107774A1 (es) | Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer | |
| EA200870261A1 (ru) | Применение пептидных соединений тро и фармацевтических композиций для лечения анемии | |
| AR082113A1 (es) | 1,3,4-oxadiazoles sustituidos, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la modulacion del receptor mch1 |